Pfizer Clinical Trial Data Errors Revealed in September Batch of Documents

As you know from prior updates, the attorneys who represent ICAN also represent the plaintiff in a lawsuit against the FDA to obtain Pfizer’s COVID-19 vaccine documents. After a historic win, the FDA was forced to produce tens of thousands of documents every month.

The September batch covers a range of information, including some interesting correspondence between FDA and Pfizer as the trial data was purportedly being validated by FDA:

  • Data validation report summary and subsequent follow-up with Pfizer – This chronological report summarizes FDA’s review of the trial data and its request to Pfizer for missing data.
  • Information request email from FDA to Pfizer – This email includes a request for “missing immunogenicity data,” also mentioned in the summary report above.
  • A death and severe adverse reaction narrative summary – This report with nearly 3,700 pages includes details of deaths and serious adverse events in the trial with “narrative comments” on some events.
  • Nine Excel files listing of data validation errors – Download the full production files to view. These spreadsheets were generated by FDA and contain trial data errors organized into various categories. It is unclear how many of these errors were later corrected by Pfizer. One of the Excel spreadsheets summarizes data errors on its “Overview” tab including:
    • 8.4% of adverse events have neither severity nor toxicity grade populated
    • 24.3% of clinical events are potential duplicates
    • 22.9% of subjects are either missing a lab test or baseline value

This production also included a few additional Case Report Forms (CRFs) which, despite their small number, included concerning adverse events:

  • A 49-year-old male was hospitalized with a myocardial infarction one week after receiving his first dose. His only reported health issue prior to that was seasonal allergies. The event was attributed to “undiagnosed obstructive CAD [coronary artery disease].” The report then listed coronary artery disease as a separate adverse event and nonsensically attributed it to “CAD.” This individual got his second dose five months later and the reason for the delay was “fever or acute illness.”
  • A 66-year-old female was hospitalized with a pulmonary embolism two months after her second dose. She had a health history that included migraines, seasonal allergies, hepatitis B, and mitral valve prolapse (a non-serious heart condition). The cause of the adverse event was listed as “HRT [hormone replacement therapy] and prolonged immobilization.”  

You can view the entire production here. ICAN will continue to update you as more files are delivered from the FDA. In the meantime, see the links below to catch up on some of ICAN’s other updates on the Pfizer documents, and click here to support our efforts.